236 related articles for article (PubMed ID: 20700120)
21. CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients.
Yazdi MF; Rafieian S; Gholi-Nataj M; Sheikhha MH; Nazari T; Neamatzadeh H
Asian Pac J Cancer Prev; 2015; 16(15):6783-7. PubMed ID: 26434912
[TBL] [Abstract][Full Text] [Related]
22. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.
Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Garne JP; Sørensen HT; Hellberg Y; Christensen M; Pedersen L; Hamilton-Dutoit S
J Natl Cancer Inst; 2011 Mar; 103(6):489-500. PubMed ID: 21325141
[TBL] [Abstract][Full Text] [Related]
23. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
Helland T; Henne N; Bifulco E; Naume B; Borgen E; Kristensen VN; Kvaløy JT; Lash TL; Alnæs GIG; van Schaik RH; Janssen EAM; Hustad S; Lien EA; Mellgren G; Søiland H
Breast Cancer Res; 2017 Nov; 19(1):125. PubMed ID: 29183390
[TBL] [Abstract][Full Text] [Related]
24. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?
Zembutsu H; Sasa M; Kiyotani K; Mushiroda T; Nakamura Y
Expert Rev Anticancer Ther; 2011 Feb; 11(2):185-93. PubMed ID: 21342038
[TBL] [Abstract][Full Text] [Related]
25. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?
Brauch H; Jordan VC
Eur J Cancer; 2009 Sep; 45(13):2274-83. PubMed ID: 19592233
[TBL] [Abstract][Full Text] [Related]
26. Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.
Stingl JC; Parmar S; Huber-Wechselberger A; Kainz A; Renner W; Seeringer A; Brockmöller J; Langsenlehner U; Krippl P; Haschke-Becher E
Curr Med Res Opin; 2010 Nov; 26(11):2535-42. PubMed ID: 20849243
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.
Thompson AM; Johnson A; Quinlan P; Hillman G; Fontecha M; Bray SE; Purdie CA; Jordan LB; Ferraldeschi R; Latif A; Hadfield KD; Clarke RB; Ashcroft L; Evans DG; Howell A; Nikoloff M; Lawrence J; Newman WG
Breast Cancer Res Treat; 2011 Jan; 125(1):279-87. PubMed ID: 20809362
[TBL] [Abstract][Full Text] [Related]
28. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Goetz MP; Sangkuhl K; Guchelaar HJ; Schwab M; Province M; Whirl-Carrillo M; Symmans WF; McLeod HL; Ratain MJ; Zembutsu H; Gaedigk A; van Schaik RH; Ingle JN; Caudle KE; Klein TE
Clin Pharmacol Ther; 2018 May; 103(5):770-777. PubMed ID: 29385237
[TBL] [Abstract][Full Text] [Related]
29. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.
Abraham JE; Maranian MJ; Driver KE; Platte R; Kalmyrzaev B; Baynes C; Luccarini C; Shah M; Ingle S; Greenberg D; Earl HM; Dunning AM; Pharoah PD; Caldas C
Breast Cancer Res; 2010; 12(4):R64. PubMed ID: 20731819
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.
Mbavha BT; Thelingwani RS; Chikwambi Z; Nyakabau AM; Masimirembwa C;
Br J Clin Pharmacol; 2023 Oct; 89(10):3209-3216. PubMed ID: 37337448
[TBL] [Abstract][Full Text] [Related]
31. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
Nardin JM; Schroth W; Almeida TA; Mürdter T; Picolotto S; Vendramini ECL; Hoppe R; Kogin JP; Miqueleto D; de Moraes SDR; Schwab M; Pecoits-Filho RF; Brauch H; Casali-da-Rocha JC
Clin Transl Sci; 2020 Mar; 13(2):284-292. PubMed ID: 31573754
[TBL] [Abstract][Full Text] [Related]
32. Tamoxifen and CYP2D6: a contradiction of data.
Hertz DL; McLeod HL; Irvin WJ
Oncologist; 2012; 17(5):620-30. PubMed ID: 22531359
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.
Zembutsu H
Pharmacogenomics; 2015; 16(3):287-96. PubMed ID: 25712191
[TBL] [Abstract][Full Text] [Related]
34. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
[TBL] [Abstract][Full Text] [Related]
35. Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.
Karle J; Bolbrinker J; Vogl S; Kreutz R; Denkert C; Eucker J; Wischnewsky M; Possinger K; Regierer AC
Breast Cancer Res Treat; 2013 Jun; 139(2):553-60. PubMed ID: 23686417
[TBL] [Abstract][Full Text] [Related]
36. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
[TBL] [Abstract][Full Text] [Related]
37. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
Bijl MJ; van Schaik RH; Lammers LA; Hofman A; Vulto AG; van Gelder T; Stricker BH; Visser LE
Breast Cancer Res Treat; 2009 Nov; 118(1):125-30. PubMed ID: 19189212
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
Higgins MJ; Rae JM; Flockhart DA; Hayes DF; Stearns V
J Natl Compr Canc Netw; 2009 Feb; 7(2):203-13. PubMed ID: 19200418
[TBL] [Abstract][Full Text] [Related]
39. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
Ahern TP; Hertz DL; Damkier P; Ejlertsen B; Hamilton-Dutoit SJ; Rae JM; Regan MM; Thompson AM; Lash TL; Cronin-Fenton DP
Am J Epidemiol; 2017 Jan; 185(2):75-85. PubMed ID: 27988492
[TBL] [Abstract][Full Text] [Related]
40. Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.
Goetz MP; Suman VJ; Couch FJ; Ames MM; Rae JM; Erlander MG; Ma XJ; Sgroi DC; Reynolds CA; Lingle WL; Weinshilboum RM; Flockhart DA; Desta Z; Perez EA; Ingle JN
Clin Cancer Res; 2008 Sep; 14(18):5864-8. PubMed ID: 18794098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
